Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
34 participants
INTERVENTIONAL
2026-02-14
2026-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secretomes contain various cytokines and growth factors, one of which is transforming growth factor (TGF)-β. TGF-β is primarily secreted by fibroblasts (FB) and, to a lesser extent, by keratinocytes, and plays a crucial role in regulating melanocyte function. TGF-β has been reported to inhibit cAMP/protein kinase A signaling and induce GLI2, which then suppresses microphthalmia-associated transcription factor (MITF), a central transcription factor in melanogenesis. A study by Moon et al. in Korea examined TGF-β3. Moon et al. examined the effects of TGF-β3 on melanogenesis in human melanocytes co-cultured with skin cells irradiated with ultraviolet (UV) light, and in UV-irradiated human skin. The results showed that UVB irradiation or stem cell factor (SCF)/endothelin-1 (ET-1) increased melanogenesis. TGF-β3 effectively inhibited melanin accumulation and tyrosinase activity by downregulating the extracellular signal-regulated kinase (ERK)/microphthalmia-associated transcription factor (MITF) pathway. TGF-β3 increased the expression of keratinocyte differentiation markers.
Mechanistically, TGF-β3 inhibits melanogenesis by inhibiting MITF expression, which is regulated by ERK. TGF-β1 reduces MITF but at the risk of inducing skin fibrosis. However, in the study by Moon et al., the aforementioned TGF Beta 1 function was not found in TGF-β3. Furthermore, TGF-β3 restored skin differentiation function in UV-irradiated keratinocytes.
To date, there have been no clinical trials comparing intradermal injection of concentrated secretome with intradermal injection of concentrated secretome with the addition of TGF-β3 as a melasma therapy in Indonesia, thus encouraging researchers to conduct further research.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy
NCT06516419
Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration
NCT06221787
Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Melasma
NCT06677931
Comparison of Chemical Peeling Agent With Transamine for Treatment of Melasma
NCT05362500
Combined Therapy of Photoelectric Instruments and Human Umbilical Cord Mesenchymal Stem Cells for Pigmentary Disorders
NCT06911281
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Melasma is a disorder with multifactorial causes. Several trigger factors for melasma include genetic predisposition, exposure to ultraviolet (UV) light, hormonal influences, pregnancy, cosmetic use, consumption of photosensitizing medications, stress, and oxidative stress. One of the main triggering factors that can worsen melasma lesions is UV light.
Melasma impacts a person's appearance, causing psychosocial and emotional disturbances and a decreased quality of life. Generally, melasma patients often complain of embarrassment, low self-confidence, dissatisfaction, and a lack of desire to travel.According to the WHO, quality of life is an individual's perception of their position in life, both in the context of culture, value systems, goals, expectations, standards, and concerns. In 2003, Balkhrisnan et al. developed a Melasma Quality of Life Scale (MELASQoL) questionnaire consisting of 10 questions to assess the effects of melasma on emotional aspects, social relationships, and daily activities.12 The MELASQoL questionnaire contains questions covering 3 domains, namely emotional conditions (questions 1-4), social life (questions 5-7, and 10), and recreation (questions 8-9). A study by Aditya et al. has validated and assessed the reliability of the MELASQoL questionnaire prepared in Indonesian, namely MELASQoL-INA. The higher the MELASQoL score, the lower the person's quality of life.
Various treatment modalities are available for melasma, but none are satisfactory, and relapses often occur after therapy is discontinued.15,16 The mainstay of melasma therapy is sun avoidance and the use of broad-spectrum sunscreen. Other primary treatments for melasma include eliminating causative factors and using bleaching agents, such as hydroquinone (HQ). Hydroquinone at a concentration of 2-5% as a single therapy or in combination with tretinoin and topical corticosteroids (triple combination cream) is the gold standard for melasma therapy. However, this therapy has side effects if used long-term and without proper monitoring. Therefore, a more effective treatment modality is needed for melasma treatment.
Technological advances have resulted in the development of cosmeceutical products derived from natural and synthetic ingredients, some of which have been clinically and empirically tested and successfully commercialized. In Indonesia, the cosmetics industry market is growing relatively rapidly, with total cosmetic product sales in 2017 (Rp9.76 trillion) increasing by 12.9% compared to 2016 (Rp8 trillion), and cosmetic exports increasing by 20% with a transaction value of US$406 million. This indicates that researchers and developers in the cosmetics industry are continuously innovating to find new compound combinations or other modalities to support the growth of the cosmetics market.
One therapeutic modality currently being developed for melasma is secretome. Secretome is a bioactive molecule secreted by mesenchymal stem cells in a conditioned medium containing a large number of growth factors, cytokines, and various macromolecules, as well as extracellular vesicles, including microvesicles and exosomes, that can stimulate various biological reactions, particularly in modulating various new tissue formations. Secretome can provide a depigmenting effect by increasing the proliferation and migration of epidermal keratinocytes, which contain melanin pigment, in line with increased fibroblast synthesis.
Secretomes contain various cytokines and growth factors, one of which is transforming growth factor (TGF)-β. TGF-β is predominantly secreted by fibroblasts (FB) and to a lesser extent by keratinocytes and plays a crucial role in regulating melanocyte function. TGF-β has been reported to inhibit cAMP/protein kinase A signaling and induce GLI2, which in turn suppresses microphthalmia-associated transcription factor (MITF), a central transcription factor in melanogenesis. A study by Moon et al. in Korea examined TGF-β3. Moon et al. examined the effects of TGF-β3 on melanogenesis in human melanocytes co-cultured with skin cells irradiated with ultraviolet (UV) light, and in UV-irradiated human skin. The results showed that UVB irradiation or stem cell factor (SCF)/endothelin-1 (ET-1) increased melanogenesis. TGF-β3 effectively inhibited melanin accumulation and tyrosinase activity by downregulating the extracellular signal-regulated kinase (ERK)/microphthalmia-associated transcription factor (MITF) pathway. TGF-β3 increased the expression of keratinocyte differentiation markers.
Mechanistically, TGF-β3 inhibits melanogenesis by inhibiting MITF expression, which is regulated by ERK. 27,28 TGF-β1 reduces MITF but at the risk of inducing skin fibrosis. However, in the study by Moon et al., mentioned function of TGF Beta 1 was not found in TGF-β3. Furthermore, TGF-β3 restored skin differentiation function in UV-irradiated keratinocytes.
To date, no clinical trials have compared intradermal injection of concentrated secretome with intradermal injection of concentrated secretome with the addition of TGF-β3 as a melasma therapy in Indonesia, prompting researchers to conduct further research. The examination parameters include the mMASI score, mexameter score, dermoscopy, and Wood's lamp. Wood's lamp examination is used to help identify the location of melanin pigment in melasma lesions. Dermoscopy is a non-invasive examination to visualize subsurface structures that are invisible to the naked eye. Mexameter is a fast, easy, and accurate spectrometer measurement technique for measuring the melanin index and erythema index in skin based on light reflection and absorption. The mexameter examination functions to measure the severity of melasma objectively.33 The severity of melasma and evaluation of therapy response can be assessed subjectively using the mMASI score.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Secretome raw material group
Group A, the treatment group, used Secretome (raw material) 3ml Intradermal injection, Sunscreen in the morning and used Tretinoin cream 0,05% at night and cleanser which was used in the morning and evening before using the cream.
Concentrated secretome Injection 3 mL
The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
Concentrated secretome Injection 3 mL with addition of TGF Beta 3
The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method after the secretome is ready, TGF beta 3 will be added to secretome
Secretome raw material with addition of TGF Beta 3 group
Group B, the treatment group, used Secretome (raw material) 3ml with addition of TGF Beta 3 Intradermal injection, Sunscreen in the morning and used Tretinoin cream 0,05% at night and cleanser which was used in the morning and evening before using the cream.
Concentrated secretome Injection 3 mL
The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
Concentrated secretome Injection 3 mL with addition of TGF Beta 3
The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method after the secretome is ready, TGF beta 3 will be added to secretome
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Concentrated secretome Injection 3 mL
The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
Concentrated secretome Injection 3 mL with addition of TGF Beta 3
The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method after the secretome is ready, TGF beta 3 will be added to secretome
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women without melasma and have areas of skin that are clinically free of lesions for SP control.
* 30-60 years old.
* Fitzpatrick skin type IV-V.
* Willing to be a research subject by signing a research consent form (Informed Consent).
Exclusion Criteria
* Currently using hormonal contraception or have ever used contraception hormones in the last 6 months.
* Using topical therapy for melasma, for example corticosteroids, tretinoin, hydroquinone, and other therapies that whiten or brighten the skin in the last 2 weeks.
* Using topical triple combination cream therapy for at least 3 months and did not show significant improvement
* Using systemic therapy for melasma, for example antioxidants or tranexamic acid in the last 4 weeks.
* History of superficial peeling therapy in the last 4 weeks.
* History of deep peeling therapy, laser or mechanical abrasion in the last 6 months.
* Using drugs that are photosensitizers such as tetracycline, phenytoin, carbamazepine, spironolactone.
* History of blood clotting disorders or on blood thinning therapy.
* Allergy to tranexamic acid.
* Have other skin complaints that may interfere with the evaluation of melasma, for example post-inflammatory hyperpigmentation, Hori's nevus, Ota's nevus, pigmented contact dermatitis, and other pigmentation disorders
* Difficulty complying with treatment.
30 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indonesia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr.dr.Irma Bernadette, SpKK (K)
Prof. M.D, Ph.D (Principal Investigator and Clinical Professor)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Cipto Mangunkusumo Hospital
Central Jakarta, D.k.i Jakarta, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Prof. Dr. dr. Irma Bernadette S. Sitohang, Sp.DVE, Subsp.DKE IBSS Irma IBSS M.D, Ph.D, M.D, Ph.D
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
irma bernadette IBS Irma Bernadette, M.D, Ph.D, M.D, Ph.D
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Moon HR, Jung JM, Kim SY, Song Y, Chang SE. TGF-beta3 suppresses melanogenesis in human melanocytes cocultured with UV-irradiated neighboring cells and human skin. J Dermatol Sci. 2020 Aug;99(2):100-108. doi: 10.1016/j.jdermsci.2020.06.007. Epub 2020 Jun 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TGF B3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.